-

11:42:26 AM

GPCR Stock News

GPCR - Structure Therapeutics Inc

06/07/23 8:30 AM

Nasdaq : GPCR

low float

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that clinical and preclinical

RHEA-AI

neutral

05/31/23 4:30 PM

Nasdaq : GPCR

conferenceslow float

Structure Therapeutics to Present at Jefferies Healthcare Conference

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., the

RHEA-AI

neutral

05/25/23 4:30 PM

Nasdaq : GPCR

clinical triallow float

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and formulation bridging study planned to evaluate tablet formulation in preparation for global Phase 2b

RHEA-AI

neutral

05/18/23 4:30 PM

Nasdaq : GPCR

low float

Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global

RHEA-AI

neutral

05/11/23 4:30 PM

Nasdaq : GPCR

earningslow float

Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Structure Therapeutics Inc.

RHEA-AI

neutral

03/30/23 4:30 PM

Nasdaq : GPCR

earningslow float

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Structure Therapeutics Inc.

RHEA-AI

neutral

02/07/23 4:00 PM

Nasdaq : GPCR

IPOofferinglow float

Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previously

RHEA-AI

neutral

02/04/23 12:15 AM

Nasdaq : GPCR, SDGR

low float

Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq

Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at

RHEA-AI

very positive

02/02/23 7:41 PM

Nasdaq : GPCR

IPOofferinglow float

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized

RHEA-AI

neutral